|
[1]KOUDAH S,EL MOUHADI S,ARRIVL.Fibrolamellar hepatocellular carcinoma[J].Clin Res Hepatol Gastroenterol,2012,36(1):5-6.
|
|
[2]YANG M,YUAN JQ,BAI M,et al.Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma:a systematic review and meta-analysis[J].Mol Biol Rep,2014,41(10):6575-6582.
|
|
[3]ZHANG L,HU P,CHEN X,et al.Transarterial chemoembolization(TACE)plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma:a meta-analysis[J].PLoS One,2014,9(6):e100305.
|
|
[4]NITTA H,BEPPU T,IMAI K,et al.Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion[J].World J Surg,2013,37(5):1034-1042.
|
|
[5]KEE KM,HUNG CH,WANG JH,et al.Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib[J].Onco Targets Ther,2014,7:829-834.
|
|
[6]IMEDIO ER,BEVERIDGE RD,URTASUN JA,et al.Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma:a single center experience[J].Med Oncol,2014,31(5):948.
|
|
[7]GADALETA-CALDAROLA G,INFUSINO S,GALISE I,et al.Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma:a phaseⅡstudy[J].Oncol Lett,2014,8(4):1783-1787.
|
|
[8]RICKE J,BULLA K,KOLLIGS F,et al.Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma:analysis of the European multicentre trial SORAMIC[J].Liver Int,2015,35(2):620-626.
|
|
[9]LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
|
|
[10]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
|
|
[11]RONOT M,BOUATTOUR M,WASSERMANn J,et al.Alternative response criteria(Choi,European association for the study of the liver,and modified response evaluation criteria in solid tumors[RECIST])versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib[J].Oncologist,2014,19(4):394-402.
|
|
[12]YADA M,MASUMOTO A,MOTOMURA K,et al.Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma[J].World J Gastroenterol,2014,20(35):12581-12587.
|
|
[13]ZHENG YB,ZHAN MX,ZHAO W,et al.The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib[J].Med Oncol,2014,31(10):209.
|
|
[14]SO BJ,BEKAII-SAAB T,BLOOMSTON MA,et al.Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis:a case report[J].J Hematol Oncol,2008,1:18.
|
|
[15]LULLA PD,BRAMMER JE,BANDEALI S,et al.Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib[J].J Gastrointest Cancer,2013,44(1):98-101.
|
|
[16]WANG SX,BYRNES A,VERMA S,et al.Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib:a case report[J].Target Oncol,2010,5(1):59-63.
|
|
[17]SHOMURA M,KAGAWA T,SHIRAISHI K,et al.Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma[J].World J Hepatol,2014,6(9):670-676.
|
|
[18]AKUTSU N,SASAKI S,TAKAGI H,et al.Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy[J].Int J Clin Oncol,2015,20(1):105-110.
|
|
[19]TANOGLU A,KARAGOZ E.Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib[J].Asian Pac J Cancer Prev,2014,15(2):1063.
|
|
[20]SHAO YY,LIN ZZ,HSU C,et al.Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma[J].Cancer,2010,116(19):4590-4596.
|
|
[21]LEE S,KIM BK,KIM SU,et al.Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy:a Korean multicenter study[J].J Gastroenterol Hepatol,2014,29(7):1463-1469.
|
|
[22]TSUCHIYA K,ASAHINA Y,MATSUDA S,et al.Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma[J].Cancer,2014,120(2):229-237.
|
|
[23]NAGAI H,KANEKAWA T,KOBAYASHI K,et al.Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib[J].Cancer Chemother Pharmacol,2014,73(2):223-229.
|
DownLoad: